Giuseppe Battaglia, leader of the IBEC “Molecular Bionics” group and ICREA Research Professor appears in various media for his recent study describing a mechanism and conditions that allow molecules to efficiently cross the blood-brain barrier, the protective layer of the brain.
The Institute for Bioengineering of Catalonia (IBEC) launches the Faster Future “A por la COVID19” campaign, with the aim of raising the 100.000€ needed to accelerate three research projects in collaboration with hospitals and patients associations.
An international study led by IBEC researcher Giuseppe Battaglia identifies a mechanism and conditions that allow molecules to efficiently cross the blood-brain barrier, the protective layer of the brain. This study describes the role of protein LRP1, bringing light to safe and efficient entrance of drugs to the brain.
Imaginenano2020 Online Imaginenano2020 organisers have been closely monitoring global developments of the COVID-19 virus since the start of the year. The health and safety of our speakers, exhibitors, participants and staff being our number one priority, we decided to postpone the in-person event to 2021 but organise a 3 days online…
In a new study published in the scientific journal Nature Communications, researchers describe a new concept called “range selectivity”, explaining why biomimetic nanoparticles only bind to receptors when their density is within a precise range.
This finding could pave the way for the development of highly targeted therapies against a number of diseases.
An international team, led by Profs Giuseppe Battaglia and Loris Rizzello from the Institute for Bioengineering of Catalonia (IBEC), carried out out a study that opens the door to a new therapy capable of quickly and effectively eliminating infections caused by intracellular bacteria, the most resistant to immune defenses.
This therapy, based on synthetic vesicles, could considerably reduce the dose and duration of antimicrobial treatments, thus reducing the danger of generating resistance to antibiotics of pathogens such as those leading to tuberculosis.
A team of international scientists led by the Institute for Bioengineering of Catalonia (IBEC) has developed a “faster, more effective and safer” therapy to eliminate infections of intracellular bacteria that cause diseases such as tuberculosis. Scientists participating in the study include Group Leader Giuseppe Battaglia and the researcher Loris Rizzello of IBEC.
Researchers at Institute for Bioengineering of Catalonia (IBEC) have proposed a model that gives important insights into how nanoparticles interact with cells, virus, bacteria or proteins, among others.
The findings provide a very powerful tool to design personalized nanomedicines, since allow the scientists to create nanoparticles tailor-made for each patient.